SCHEMBL10134359

SCHEMBL10134359

O=c1cc(-c2ccc(Nc3ccc(N4CCOCC4)c(F)c3)c3nccn23)cc[nH]1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 9/20 0.59
JAK2 O60674 2/20 0.41
JAK3 P52333 2/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
HTT P42858 1/20 0.40
LRRK2 Q5S007 1/20 0.39
PIK3CA P42336 1/20 0.39
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
DGAT1 O75907 1/20 0.38
SYK P43405 1/20 0.38
FYN P06241 1/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13922277 0.90 MAPKAPK5 (0.59) MAPKAPK5JAK2JAK3JAK1TYK2
SCHEMBL10134531 0.88 MAPKAPK5 (0.48) MAPKAPK5JAK2JAK3JAK1SYK
SCHEMBL10134371 0.88 MAPKAPK5 (0.75) MAPKAPK5JAK2LRRK2MAPK10SYK
SCHEMBL12618841 0.84 MAPKAPK5 (0.63) MAPKAPK5LRRK2PIK3CASYKFYN
SCHEMBL12618840 0.84 MAPKAPK5 (0.63) MAPKAPK5JAK2LRRK2PIK3CAMAPK10
SCHEMBL10134525 0.84 MAPKAPK5 (0.46) MAPKAPK5
SCHEMBL1685175 0.83 MAPKAPK5 (0.50) MAPKAPK5JAK2JAK3LRRK2MAPK9
SCHEMBL10134376 0.83 MAPKAPK5 (0.57) MAPKAPK5JAK2JAK3JAK1TYK2
SCHEMBL10134367 0.82 MAPKAPK5 (0.64) MAPKAPK5JAK2JAK3HTTMAPK9
SCHEMBL12618515 0.81 MAPKAPK5 (0.44) MAPKAPK5JAK2JAK3HTTMAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885JAK2 1510/4885JAK3 1803/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885JAK2 1510/4885JAK3 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.